SYT (SS18) Breakapart
Synovial sarcomas account for up to 10% of soft-tissue sarcomas, typically arising in the para-articular regions in adolescent and young adults1.
A characteristic SYT(SS18)-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11.2) is detectable in more than 90% of synovial sarcomas2, suggesting this is the primary causal event. The translocation fuses the SYT gene from chromosome 18q11.2 to either of two highly homologous genes at Xp11: SSX1 (Synovial Sarcoma X Breakpoint 1) or SSX2. In less than 1% of cases, SYT will be fused to a third gene, SSX43. SYT-SSX1 and SYT-SSX2 are thought to disrupt transcription and the subsequent expression of specific target genes4,5.
1. Enzinger FM, Weiss SW. Synovial sarcoma. In: Enzinger FM, Weiss SW, eds. Soft tissue tumors, 3rd ed. St. Louis: Mosby-Year Book, 1995:757–86
2. Sreekantaiah et al., Am J Pathol 1994;144:1121-34
3. Ladanyi et al., Canc Res 2002;62:135-40
4. Ladanyi et al., Diagn Mol Pathol 1995;4:162-73
5. Sorensen, Triche, Semin Cancer Biol 1996;7:3-14
- Area of Interest*
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.